BAD抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using BAD mouse mAb against MCF-7 (1), HEK293 (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using BAD mouse mAb (green) and negative control (red).    

  
  

BAD (BCL2-associated agonist of cell death) is a pro-apoptotic protein belonging to the BCL-2 family, which regulates mitochondrial-mediated apoptosis. It promotes cell death by binding and neutralizing anti-apoptotic proteins like BCL-2 or BCL-XL, thereby activating pro-apoptotic effectors such as BAX/BAK. However, BAD's activity is tightly controlled by survival signals. Phosphorylation at specific serine residues (e.g., Ser112. Ser136. and Ser155) by kinases like AKT, PKA, or RSK inhibits its pro-apoptotic function, facilitating interaction with 14-3-3 proteins and cytoplasmic sequestration. Dysregulation of BAD is implicated in diseases such as cancer, neurodegeneration, and metabolic disorders.

BAD antibodies are essential tools for studying its expression, post-translational modifications, and interactions. They enable detection of BAD's phosphorylation status, which reflects cellular survival signaling, and are used in techniques like Western blotting, immunohistochemistry, and flow cytometry. Researchers employ these antibodies to explore BAD's role in apoptosis regulation, drug resistance mechanisms, and therapeutic targeting. For instance, in cancer, BAD expression or phosphorylation levels may correlate with prognosis or chemosensitivity. High-quality, specific BAD antibodies are critical for distinguishing between its active and inactivated forms, aiding both basic research and translational studies.